COLUMBUS, Ohio, Oct. 22 Last week, Roxane Laboratories,Inc. launched its calcium acetate capsules, 667mg. Since the October 15exclusive launch of this product, Roxane Laboratories, Inc., hasexperienced tremendous demand.
Roxane Laboratories' calcium acetate capsules, 667mg are the only AB ratedgeneric alternative to PhosLo(R) (calcium acetate) capsules, used in thetreatment of high levels of phosphate in patients with chronic renal failure.Annual sales of PhosLo(R) (calcium acetate) capsules are approximately $84.8million(1).
Full prescribing information for calcium acetate capsules, 667mg isavailable on the Roxane Laboratories website at www.Roxane.com or upon requestby calling Roxane Laboratories Technical Product Information hotline at1-800-962-8364.
About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 squarefoot manufacturing and laboratory facility. The facility spans 70 acres andcurrently employs over 1,000 people. Currently, Roxane Laboratoriesmarkets over 75 medications in nearly 250 package sizes, focusing on anexpanding line of Multisource pharmaceutical products including: bulk andunit-dose liquids and solids; coated, sustained-release and controlled releasetablets; nasal sprays, cytotoxics and CII narcotics.
Roxane Laboratories, Inc., is a subsidiary of Boehringer IngelheimCorporation, based in Ridgefield, CT and a member of the Boehringer Ingelheimgroup of companies.
About Boehringer Ingelheim
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the USheadquarters to seven subsidiaries and a member of the Boehringer Ingelheimgroup of companies.
The Boehringer Ingelheim group is one of the world's 20 leadingpharmaceutical companies. Headquartered in Ingelheim, Germany, it operatesglobally with 135 affiliates in 47 countries and approximately 39,800employees. Since it was founded in 1885, the family-owned company has beencommitted to researching, developing, manufacturing and marketing novelproducts of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9billion euro) while spending approximately one-fifth of net sales in itslargest business segment, Prescription Medicines, on research and development.
For more information on Boehringer Ingelheim, please visithttp://us.boehringer-ingelheim.com.
(1) IMS MAT dollar sales ending 6/2008
PhosLo(R) is a registered trademark of Fresenius Medical Care.
SOURCE Roxane Laboratories, Inc.